William R. Roush
42Patents
8h-index
42Co-inventors
75Inventor score
Filing activity: Aug 14, 1998 → Oct 17, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6133308A | Synthesis of clasto-lactacystin beta-lactone and analogs thereof | Chemistry; Metallurgy | 55 | Expired |
| US6294560A | Synthesis of clasto-lactacystin .beta.-lactone and analogs thereof | Chemistry; Metallurgy | 54 | Expired |
| US6849743B2 | Synthesis of clasto-lactacystin β-lactone and analogs thereof | Chemistry; Metallurgy | 53 | Expired |
| US6794516B2 | Synthesis of clasto-lactacystin &bgr;-lactone and analogs thereof | Chemistry; Metallurgy | 52 | Expired |
| US6566553B2 | Synthesis of clasto-lactacystin &bgr;-lactone and analogs thereof | Chemistry; Metallurgy | 27 | Expired |
| US10556903B2 | NLRP3 modulators | Emerging Cross-Sectional Technologies | 11 | Active |
| US10533007B2 | NLRP3 modulators | Human Necessities | 10 | Active |
| US10533005B2 | NLRP3 modulators | Human Necessities | 9 | Active |
| US10604542B2 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | Human Necessities | 4 | Active |
| US10654816B2 | Compounds and compositions for treating conditions associated with NLRP activity | Chemistry; Metallurgy | 2 | Active |
| US10329303B2 | Heterocyclic inhibitors of monocarboxylate transporter | Chemistry; Metallurgy | 2 | Active |
| US10961270B2 | Compounds and compositions for treating conditions associated with sting activity | Human Necessities | 2 | Active |
| US11072612B2 | NLRP3 modulators | Emerging Cross-Sectional Technologies | 1 | Active |
| US11344543B2 | NLRP3 modulators | Chemistry; Metallurgy | 1 | Active |
| US10851113B2 | Heterocyclic inhibitors of monocarboxylate transporters | Chemistry; Metallurgy | 1 | Active |
| US11203579B2 | Compounds and compositions for treating conditions associated with NLRP activity | Chemistry; Metallurgy | 1 | Active |
| US9493464B2 | Wee1 degradation inhibitors | Chemistry; Metallurgy | 1 | Active |
| US11724992B2 | Compounds and compositions for treating conditions associated with NLRP activity | Chemistry; Metallurgy | 0 | Active |
| US11447460B2 | Compounds and compositions for treating conditions associated with NLRP activity | Chemistry; Metallurgy | 0 | Active |
| US11618749B2 | Compounds and compositions for treating conditions associated with STING activity | Chemistry; Metallurgy | 0 | Active |
| US10723756B2 | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer | Human Necessities | 0 | Active |
| US11731934B2 | HDAC inhibitor compounds and methods of treatment | Chemistry; Metallurgy | 0 | Active |
| US10485804B2 | Therapeutic targeting of casein kinase 1δ in breast cancer | General | 0 | Revoked |
| US11370763B2 | Compounds and compositions for treating conditions associated with NLRP activity | Chemistry; Metallurgy | 0 | Active |
| US12152018B2 | Compounds and compositions for treating conditions associated with STING activity | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.